NBT Bank N.A. Buys 52,930 Shares of Bristol Myers Squibb Company $BMY

Key Points

• NBT Bank N.A. acquired 52,930 shares of Bristol Myers Squibb during the third quarter, valued at approximately $3.3 million. Institutional investors collectively own 76.41% of the company.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $64.88, while recent targets range from $53 to $82.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates, and revenue of $12.97 billion, up 5.7% year over year. The company also declared a quarterly dividend of $0.63 per share, representing a 4.0% annualized yield.

NBT Bank N.A. purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 52,930 shares of the biopharmaceutical company's stock, valued at approximately $3,303,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Lazard Asset Management LLC boosted its stake in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock valued at $116,693,000 after buying an additional 368,193 shares during the last quarter. Callan Family Office LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $3,575,000. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. Saudi Central Bank increased its stake in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company's stock worth $8,235,000 after acquiring an additional 67,780 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BMY shares. JPMorgan Chase & Co. increased their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Daiwa Securities Group boosted their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 4th. Cantor Fitzgerald reduced their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating on the stock in a research report on Thursday, October 8th. Guggenheim reaffirmed a "buy" rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Piper Sandler reiterated an "overweight" rating and set a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a research report on Wednesday, September 16th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and a consensus target price of $64.88.

Bristol Myers Squibb Trading Up 3.2%

BMY opened at $63.10 on Friday. The stock has a 50-day moving average of $63.31 and a 200 day moving average of $60.32. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The firm has a market cap of $128.89 billion, a P/E ratio of 9.39, a P/E/G ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.56 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Fresh clinical updates are putting BMY’s pipeline back in focus ahead of the ESMO 2026 Congress. Recent Phase 3 data in oncology and pulmonary fibrosis, along with the ACTION-1 study meeting its primary endpoint for RYZ101 in certain gastrointestinal neuroendocrine tumors, could support longer-term growth beyond the company’s legacy products. Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
• Positive Sentiment: Bristol Myers Squibb reported strong recent operating momentum, with second-quarter revenue of $12.97 billion, aided by Camzyos and its oncology portfolio. The ACTION-1 result has also strengthened the bullish case ahead of the October 27 earnings release. Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
• Positive Sentiment: Compared with Pfizer, BMY has delivered a steadier revenue trajectory, with continued year-over-year growth across the reviewed quarters. That consistency may appeal to investors seeking more predictable pharmaceutical revenue. Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
• Positive Sentiment: BMY and the Institute for Healthcare Improvement launched a national collaborative intended to expand access to cancer clinical trials. The initiative may improve trial participation and support the company’s broader oncology research ecosystem over time. IHI and Bristol Myers Squibb Launch National Collaborative
• Neutral Sentiment: Comparisons with Novo Nordisk, Eli Lilly and AbbVie highlight BMY’s stable scale and diversified oncology and cardiovascular portfolio, but also show that competitors have stronger exposure to faster-growing therapies or higher overall revenue growth. Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
• Negative Sentiment: Analysts expect third-quarter earnings to decline and suggest BMY may lack the typical combination of positive earnings and revenue surprises needed for a beat. This creates near-term downside risk around the October 27 report. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline
• Negative Sentiment: Generic competition is increasing across BMY’s mature portfolio, creating pressure on older products. Eliquis remains a growth driver and Revlimid has shown resilience, but investors remain concerned about the durability of legacy-drug revenue. Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.